10x Genomics, Inc. (NASDAQ:TXG) receives consensus rating of “Hold” from the brokerage

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Your Free Report ) has been assigned a consensus rating of “Hold” from the thirteen research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $31.46.

A number of equities research analysts have commented on TXG shares. Guggenheim reiterated a “neutral” rating on shares of 10x Genomics in a research report on Tuesday, June 25th. Canaccord Genuity Group decreased their target price on shares of 10x Genomics from $50.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, July 23rd. UBS Group cut their price target on 10x Genomics from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 13th. Goldman Sachs Group dropped their price objective on 10x Genomics from $26.00 to $16.00 and set a “sell” rating for the company in a research note on Tuesday, July 9th. Finally, JPMorgan Chase & Co. cut shares of 10x Genomics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $40.00 to $20.00 in a research report on Thursday, July 18th .

Check out our latest review on TXG

10x genomics trades down 1.0%

TXG opened at $22.57 on Wednesday. 10x Genomics has a 12-month low of $15.28 and a 12-month high of $57.90. The firm has a market cap of $2.69 billion, a PE ratio of -10.12 and a beta of 1.84. The company’s 50-day moving average price is $19.70 and its 200-day moving average price is $28.14.

Insider buying and selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 4,351 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $98,028.03. Following the completion of the sale, the insider now directly owns 345,704 shares of the company’s stock, valued at approximately $7,788,711.12. The transaction was disclosed in a filing with the SEC, which can be accessed via this hyperlink. In other news, CFO Justin J. Mcanear sold 2,961 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $66,711.33. Following the completion of the sale, the chief financial officer now directly owns 143,242 shares of the company’s stock, valued at approximately $3,227,242.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed via this link. Also, insider Benjamin J. Hindson sold 4,351 shares of 10x Genomics stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total value of $98,028.03. Following the completion of the sale, the insider now owns 345,704 shares in the company, valued at $7,788,711.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,061 shares of company stock worth $316,794. 10.03% of shares are owned by company insiders.

Institutional inputs and outputs

A number of hedge funds have recently added to or reduced their stakes in TXG. Algert Global LLC raised its holdings in 10x Genomics by 39.4% in the 2nd quarter. Algert Global LLC now owns 117,964 shares of the company’s stock valued at $2,294,000 after acquiring an additional 33,364 shares in the last quarter. Susquehanna Fundamental Investments LLC boosted its stake in 10x Genomics by 166.7% in the second quarter. Susquehanna Fundamental Investments LLC now owns 201,671 shares of the company’s stock worth $3,923,000 after buying an additional 126,052 shares in the last quarter. Deerfield Management Company LP Series C acquired a new position in shares of 10x Genomics during the second quarter valued at about $11,612,000. AQR Capital Management LLC increased its position in shares of 10x Genomics by 230.9% in the 2nd quarter. AQR Capital Management LLC now owns 315,180 shares of the company’s stock worth $6,130,000 after acquiring an additional 219,945 shares. shares in the last quarter. Finally, Squarepoint Ops LLC raised its holdings in 10x Genomics by 1.1% during the second quarter. Squarepoint Ops LLC now owns 515,883 shares of the company’s stock valued at $10,034,000 after purchasing an additional 5,720 shares during the last quarter. 84.68% of the shares are held by hedge funds and other institutional investors.

About 10x Genomics

(Get a free report

10x Genomics, Inc, a life science technology company, develops and sells instruments, supplies and software for the analysis of biological systems in the Americas, Europe, the Middle East, Africa, China and Asia Pacific. The company provides chrome instruments, chrome connector and chrome controller, microfluidic chips, slides, reagents and other consumable products.

See Also

Get news and reviews for 10x Genomics daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for 10x Genomics and related companies with MarketBeat.com’s FREE daily email newsletter.